High dose of d-chiro-inositol improves oocyte quality in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial

Abstract

The aim of this study was to evaluate the effect of two doses of d-chiro-inositol (DCI) in combination with Myo-inositol (MYO) on the oocyte quality (OQ) of women with polycystic ovarian syndrome (PCOS) undergoing intracytoplasmic sperm injection (ICSI). Methods: This was a controlled, randomized, double-blind, parallel group study on 172 oocytes from 11 women. The study compared the effect of two MYO-DCI formulations given over 12 weeks on OQ. Five women received 550 mg of MYO + 300 mg of DCI daily (high DCI content group), while 6 women were given a daily dose of 550 mg of MYO with the only 27.6 mg of DCI (low DCI content group). Results: According to a multivariate analysis using linear mixed effect models, high doses of DCI have a positive influence on the quality of the cytoplasm of the oocyte (β = 1.631, χ² = 7.347, d.f. = 1, p = .00672). Zona pellucida, plasma membrane, cytoplasm, and sperm reception have also been improved with any combination of MYO/DCI by decreasing testosterone or improving insulin sensitivity, regardless of age and body mass index. Conclusion: The combination of MYO with high doses of DCI improved oocyte cytoplasm quality in women with PCOS undergoing ICSI.

摘要

本研究的目的是评估两种剂量的D-手性肌醇（DCI）联合肌醇（Myo）对接受卵细胞胞浆内单精子注射（ICSI）的多囊卵巢综合征（PCOS）妇女卵母细胞质量（OQ）的影响。方法：这是一项对照、随机、双盲、平行的研究, 对11名女性的172个卵母细胞进行了研究。该研究比较了12周内给予的两种MYO-DCI制剂对OQ的影响。5名女性每天接受550mg MYO+300mg DCI（高DCI含量组）, 而6名女性每天接受550mg MYO+27.6mg DCI（低DCI含量组）。结果：根据线性混合效应模型的多变量分析, 高剂量的DCI对卵母细胞的细胞质质量具有积极影响（β=1.631,χ² = 7.347, d.f. =1, p= .00672）。透明带、质膜、细胞质和精子的接受度也通过降低睾酮或改善胰岛素敏感性的MYO/DCI的任何组合得到改善, 而与年龄和体重指数无关。结论：高剂量DCI联合MYO治疗能改善ICSI合并多囊卵巢综合征患者的卵母细胞质量。

The Chinese abstracts are translated by Prof. Dr. Xiangyan Ruan and her team: Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China.

Keywords:

• d-chiro-inositol
• PCOS
• ICSI
• oocyte quality

Acknowledgments

The statistical analyses have been made by Ramon Ferri, Department of Statistics, University of Granada. Oak-fortress Proofreading International have edited English. This study is part of the doctoral thesis of M^a Isabel Galan.

Details of ethics approval

The study was approved at each clinical site. The Ethical Committee of the principal researcher (N. Mendoza) was the Ethics Committee of Granada (CEI, Consejería de Salud).

Disclosure statement

MP Diaz-Ropero, J Fonollá and M Olivares are workers of Biosearch Life, company that produces DCI from carob fruit. The rest of the authors declare that they have no competing interests.